An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Amylyx Pharmaceuticals Inc.
Study ID
NCT07582874
Status
Available

Conditions

  • Post-bariatric Hypoglycemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Avexitide — DRUG
    90 mg subcutaneous injection once per day at least one hour prior to first meal of the day.

Study Details

The Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program. The safety of avexitide and patient treatment experience will be monitored during this program.

Key Dates

Status verified
May 2026

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Diabetes and Glandular Disease ClinicSan AntonioTexas78229-4801-

Find similar trials in San Antonio, TX

By research site
Diabetes and Glandular Disease Clinic· San Antonio, TX

Related Studies